Dermal dendritic cells (DDCs) or dermal dendrocytes are normal resident cells of the reticular dermal interstitium, occurring predominantly perivasculaiiy and within the papillary dermis. They are characterized by their highly dendritic morphology (1) . Although the origin of the DDC remains a topic of debate, the preponderance of e\idence from immunohistochemistry and immunofluorescence studies supports their derivation from bone marrow progenitor cells (2, 3) .
Most DDCs express cytoplasmic factor Xllla, a protransglutaminase involved in hemostasis (4) (5) (6) . In addition tt> their putative role in wound healing, DDCs are capable of phagocytosis of hemo.siderin, melanin, and exogenous pigments, such as are present in tattoos (1, 4, 7) .
DDCs proliferate in a variet)' of inflammatory and neoplastic processes. In inflammatory dermatoses, such as psoriasis and atopic eczema, an increase in DDCs associated with a lymphocytic infiltrate was previously reported (3) . A proliferation of factor Xllla-positive DDCs is the sine qua non of the dermatofibioma, and is also seen in fibrous papules of the face (8. 9). Moreover, DDC^ are readily identified at the periphery of Kaposi's sarcomas (10) . Denton et al. evaluated the distribution of factor XII la-positive DDCs in di.stinguishing nodtilar melanomas from Spitz nevi (11) . Tbey demonstrated tbat DDCs were either diffusely distributed within the tumor or primarily localized to the periphery, and that the pattern of distribution could not be used to distinguish between these two entities.
A proposed antigen-presenting role for DDCs is based on their proliferation and enhanced expression of HLA-DR, a class II, nonconsdtutively ex-p ressed major histocompatibility antigen, in intradermal delayed hypersensitivity reactions (1) and as potent stimulators of allogeneic mixed lymphocyte reactions in vitro (12) . Although HLA-DR expression in melanomas has been extensively studied, the primary focus has been on antigen expression in melanoma cells (13) (14) (15) (16) (17) (18) (19) . A few groups have evaluated HLA-DR expression by dendritic cells (Langerhans cells) residing within the dermis (20, 21) ; however, to our knowledge, differences in HLA-DR expression by factor Xllla-positive DDCs in radial versus vertical growth-phase melanomas has not been done.
In this study, we semiquantitatively evaluated factor Xllla expression by DDCs in benign and malignant nevomelanocytic lesions to determine if there was a hypei^plasia of DDCs and, if so, whether there specifically was a difference between radial and vertical growth-phase melanomas. Moreover, we assessed HLA-DR expression by DDCs to delineate a possible immunologic role as antigen-presenting cells in the progression of malignant melanomas.
Material and methods

Case selection
Fifty cases, 20 radial and 20 vertical growth-phase melanomas and 10 typical compound nevi, were obtained through the Melanoma Clinic registry and the SNOMED retrieval program of the Pathology Data Systems of the University of Michigan Medical Center. Cases were excluded if they were re-excisions of a previously diagnosed melanoma or compound nevus.
Radial were compared to vertical growth-phase melanomas for sex, age, body site, presence or absence of regression, and sun exposure. There were more males than females in the radial growthphase group (14 vs. 6), as opposed to slightly more females than males in the vertical growth-phase group (11 vs. 9). The mean age was not appreciably different between the two groups (radial, 56 years; vertical, 61 years). Melanomas were separated into sites as follows: head and neck (radial, 4; vertical, 5), trunk (radial, 12; vertical, 8), extremities (radial, 3; vertical, 7), and site not provided (radial, 1). Presence of regression did not differ between the two groups (radial, 5; vertical, 4). In cases with regression, it was either focal (radial, 1; vertical, 2), or diffuse (radial, 4; vertical, 2). The degree of sun exposure was determined based on the degree of elastosis seen on the original hematoxylin and eosin stained slides. There was no significant difference between radial or vertical growth-phase melanomas with respect to presence (radial, 14; vertical, 15), or degree of elastosis.
Immunoperoxidase methods
Four-pm sections of formalin-fixed, paraffin-embedded tissue were prepared on plus slides (Baxter Scientific). In the vast majority of cases, sequential slides were prepared at approximately 4-|im intervals and consecutively stained with the primary antibodies in question.
Single iabeiing
The slides were deparaffinized in xylene and ethanol. Endogenous peroxidases were blocked with hydrogen peroxide. Pretreatment with protease was done for factor Xllla and CDla stains, and microwave for CD34 (HPCA-1/2) stains; no pretreatment was done for HLA-DR (LN3). The tissues were stained with piimary antibody followed by a biotinylated, polyspecific secondary antibody and an avidin-biotin horseradish peroxidase amplification system using an automated (Ventana) method. Each case was stained with a 1:800 dilution of rabbit polyclonal antibody to factor Xllla (Becton-Dickinson), an undiluted mouse monoclonal antibody to HLA-DR (BioGenex), an undiluted mouse monoclonal antibody to CDla (Immunotecli), and a 1:10 dilution of mouse monoclonal antibody to CD34 (Becton-Dickinson). The peroxidase was visualized with 3 ,3'-diaminobenzadine (DAB). All slides were counterstained with Mayer's hematoxylin. Each antibody was applied to all 50 cases in a single run to avoid interbatch variability.
Double iabeiing
Six cases, three radial and three vertical growthphase melanomas, were double labeled with HLA-DR vs. factor Xllla, HLA-DR vs. CD34, and CD34 vs. factor Xllla. The slides were deparaffinized as above. Endogenous peroxidases were blocked with hydrogen peroxide. Microwave pretreatment was performed for optimal antigen retrieval of HLA-DR. factor Xllla, and CD34, as determined by single stain control runs using different forms of pretreatment, i.e. no pretreatment, enzyme pretreatment, or microwave pretreatment. The tissues were stained with the first primary antibody (HLA-DR for HLA-DR vs. factor Xllla or HLA-DR vs. CD34, or CD34 for CD34 vs. factor Xllla) at the same titers as above, followed by a biotinylated, polyspecific (anti-mouse and anti-rabbit) secondary antibody and an avidin-biotin horseradish peroxidase amplification system by an automated (Ventana) method. The peroxidase reaction product was detected using DAB. The slides were then subjected to the second primary antibody (factor Xllla or CD34 for HLA-DR, or factor Xllla for ('D34) followed by a biotinylated, polyspecific (anti-mouse and anti-rabbit) secondary antibody and an avidin-biotin alkaline phosphatase amplification system also using an automated (Ventana) system. The alkaline phosphatase reaction product was detected using fast red. All slides were counterstained with Mayer's hematoxylin.
Interpretation of stains
Factor XlUa, HLA-DR, CD-34, and CDla slides were interpreted for staining intensity and scored semiquantitatively on a scale of 0-3-H. The scoring system for staining intensity was as follows: 0 (none) = rare to no cells staining; \+ (slight) = low density, patchy staining; 2+ (moderate) ^ moderate density, focal or confluent paralesional staining; and 34-(marked) = high density with broad, confluent paralesional staining. Care was taken to exclude melanin-containing macrophages (melanophages) as a source of false positive staining. Moreover, distinguishing lymphocyte from DDC staining with HLA-DR was important in avoiding a false positive interpretation; this was readily achieved on morphologic grounds.
Statisticai anaiysis
Chi-square analysis was performed using Sigma Stat 2.0 .software (Jandel Scientific, San Raphael, Ca) run on a Compaq Desk pro 590 PC. Statistical significance was assigned at the p<0.05 level. 
Results
Factor Xiiia staining
Four of 10 (40%) compound nevi, 9 of 20 (45%) radial growth-phase melanomas, and 12 of 20 (60%) vertical growth-phase melanomas showed an increase in factor Xllla staining of DDCs (Table 1). The majority of cases, with the exception of 3 vertical growth-phase melanomas, had only slight (1-I-) increased staining (Fig. 1) . Wlien compared to compound nevi, there was no statistical difference in factor Xllla staining for radial (p=1.00) or vertical (p=0.44) growth-phase melanomas.
HLA-DR staining
Two of 10 (20%) compound iie\i and 17 each of 20 (85%) radial and vertical growth-phase melanomas showed HLA-DR expression by DDCs ( Table 2 ). The majority of cases showed slight HLA-DR staining (Fig. 2) . However, in 7 of 17 (41%) radial and 6 of 17 (35%) vertical growthphase melanomas, the intensity of staining was judged to be moderate (2+) (Fig. 3) . HLA-DR expression was judged to be similar in both melanoma groups, but was significantly increased in both melanoma groups when compared to compound nevi (p<0.001). Of particular interest, HLA-DR expression by DDCs appeared to correlate with the presence or absence of a lymphocytic infiltrate in both radial and vertical growth-phase melanomas. Furthermore, the intensity of staining was greater in the presence of a brisk and infiltrative lymphocytic host response, whereas the intensity of staining was less or absent in a nonbrisk and noninfiltrative or absent lymphocytic host response (Fig. 3) .
CD1 a Staining
Two of 10 (20%) compound nevi, 3 of 20 (15%) radial growth-phase melanomas, and 5 of 20 (25%) vertical growth-phase melanomas demonstrated slight (1+) increased CDla staining of cells in the superficial dermis (Table 3 ). There was good internal control staining of CDla-positive Langerhans cells within the epidermis. The Langerhans cells within the derinis tended to cluster as a few cells around blood vessels in association with a lymphocytic infiltrate of variable intensity. However, most lesions demonstrating a lymphocytic host response, including both radial and vertical growthphase melanomas, did not show cells staining for CDla within the dermis. Based on the few cases with CDla-positive cells in the derinis and the small number of cells that were tighdy distributed around blood vessels in a very focal pattern, it is apparent that these cells did not significantly contribute to the HLA-DR expression seen iti DDCs.
CD34 staining
Seven of 10 (70%) and 2 of 10 (20%) compound nevi showed slight (l-i-) and moderate (2+) CD34 staining, respectively. Eight of 20 (40%), 6 of 20 (30%), and 3 of 20 (15%) radial growth-phase melanomas showed slight, moderate, and marked CD34 staining, respectively. No vertical growthphase melanomas had marked staining; however, 5 of 20 (25%) had slight and 5 of 20 (25%) had moderate staining ( Table 4 ). DDCs that stained with CD34 had morphologic features indistinguishable from factor Xllla-positive DDCs, althotigh those CD34-positive DDCs within the interstitium tended to be more evenly distributed from upper to deep dermis. When increased staining was observed, it was usually seen within DDCs along the base or periphery of the lesion. CD34-positive DDCs were located both perivascularly and within the dermal interstitium. As expected, CD34 also stained endothelial cells, as well as dendritic cells within the connective tissue surrounding eccrine coils. Since the vascularity varied, in some cases significantly, from case to case, no attempt was made to factor out the contribution of vascular staining to the total score, as reproducibility would be difficult to achieve.
Double labeling
In 4 of 6 melanoma cases (radial, 2; vertical, 2) on which double labeling for HLA-DR vs. factor Xllla was performed, frequent factor Xllla-positive DDCs coexpressing HLA-DR weie seen (Fig. 4) . There did not appear to be a difference between radial and vertical growth-phase melanomas in number of DDCs staining with both factor Xllla and HLA-DR. However, there were other cells, mosdy lymphocytes but occasional factor Xlllanegative DDCs, expressing only HLA-DR. Occasional factor Xllla-positive DDCs did not show HLA-DR coexpression. Two cases showed strong HLA-DR staining but very weak and patchy factor Xllla staining; these cases were considered unreliable for interpretation. It is possible that antigen retrieval for factor Xllla by microwaving was suboptimal on these two cases.
When CD34 and factor Xllla were applied in our double labeling techniqtie, DDCs were readily identified with restricted staining for either CD34 or factor Xllla in 3 of 6 cases (Fig. 5) . No DDCs coexpressiug both epitopes were seen. In 3 of 6 cases, CD34 stained DDCs well; however, factor Xllla Staining was weak and focal. Therefore, as with a few cases of HLA-DR vs. factor Xllla, these cases were considered unreliable for interpretation.
CD34 was stained against HLA-DR to see if any CD34-positive DDCs may coexpress HLA-DR, possibly accounting for the occasional DDCs expressing HLA-DR that were factor XIIla-negative. Five of 6 cases showed strong staining for both HLA-DR and CD34. No CD34 DDCs were observed to coexpress HLA-DR. In one case, HLA-DR staining was strong btit CD34 staining was absent. Therefore, this case was considered unreliable for interpretation.
Discussion
In contrast to fibroproUferative lesions, such as dermatofibromas or fibrous papules of the face, (here was no significant hyperplasia of DDCs, as determined by cytoplasmic factor Xllla labeling, in the nevomelanocytic lesions we evaluated. Our postulate that DDCs would be increased above background in invasive melanomas when compared to a benign nevomelanocyt:ic control group was not confirmed in this study. Moreover, if DDCs increased in invasive melanomas, either due to proliferation or recruitment, we hypothesized that the number of DDCs would be either unchanged or, more likely, reduced in vertical growth-phase melanomas when compared to radial growthphase melanomas. We found no difference in the number of factor XIIla-positive DDCs between vertical and radial growth-phase melanomas, as determined semiquantitatively. Radial and vertical growth-phase melanomas are associated with a significantly increased expression of HLA-DR by DDCs in single antibody immunoperoxidase studies, suggesting that DDCs may have an antigen-presenting role in the dermal immune response to invasive melanomas. This is perhaps not surprising, since HLA-DR expression hy DDCs in inti"adermal delayed hypersensitivity reactions has been described (1) . In order to confirm that factor Xllla-positive cells may coexpress HLA-DR, we subjected a small subset of radial and vertical growth-phase melanomas to an immunoperoxidase double labeling technique. We found that some factor Xllla-positive DDCs coexpress HLA-DR (cells with cytoplasmic staining for both antigens), thereby confirming our impression from single antibody studies. We acknowledge the remote possibility of cross reacti\'ity in our double labeling experiment, since the secondary antibody used against both primary antibodies was polyspecific. However, based on the pattern of DDCs staining for HLA-DR and factor Xllla, i.e. coexpression as well as cells with restricted staining with both antibodies, purely restricted staining within DDCs for either CD34 or factor Xllla, and cells with either CD34 or HLA-DR expression, we are confident that al! of the binding sites on the
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initial polyspecific secondary antibody were adequately blocked by the avidin-biotin amplification system such that no sites were available for cross reacti\'ity.
In most radial and vertical growth-phase melanomas, HLA-DR expressing DDCs were found in association with the host lymphocytic inflammatory response and, more importantly, appeared to be associated with a brisk and infiltrative lymphocytic response as described by Elder and coworkers (22, 23) . This finding may further support a putative antigen-presenting role by DDCs to tumor infiltrating lymphocytes.
The DDC remains an under studied cell in the dermal immune response to the wide range of inflammatory and neoplastic processes that involve the skin. Additional studies of HLA-DR-expressing DDCs in melanomas with a brisk and infiltrative lymphocytic host response compared to melanomas with a brisk and noninfiltrative, nonbrisk, or absent lymphocytic host response should be done.
